CytoMed Therapeutics Limited (GDTC) Stock Price & Analysis
CytoMed Therapeutics Limited (GDTC) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $0.755 (-2.33%), as of the Nov 20, 2026 trading session; market cap $9.01M.
Educational signal · not a buy or sell recommendation · How to read this
CytoMed Therapeutics Limited · GDTC · NASDAQ
CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company based in Singapore, specializing in innovative cell-based immunotherapies for cancer treatment.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · CytoMed Therapeutics (GDTC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and an expensive valuation, though the balance sheet and growth are only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.
- quarterly revenue S$157,289 (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 0 of the last 3 reports
- Altman Z -1.96 · Piotroski F 3
Holding back: weak fundamentals, a rich price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 20 | Weak | |
| 24 | Weak | |
| 24 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.755 | |
| Change on the day | -2.33% | |
| 52-week range | $0.68 – $2.29 | |
| Market capitalisation | $9.01M | — |
| Shares traded on the day | 15.5K |
Price & events
Other perspectives
Council score for CytoMed Therapeutics (GDTC): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is CytoMed Therapeutics (GDTC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CytoMed Therapeutics Limited (GDTC) is listed on NASDAQ. It employs 42 people and is led by Chee Kong Choo. In Q2 FY2026 it reported revenue of S$157,289 and net income of -S$2M. The market values it at $9.01M.
What do the latest results show for CytoMed Therapeutics (GDTC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of S$157,289. Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | S$157,289 | -S$2M | -S$0.15 (diluted) |
| Q1 FY2026 | S$189,440 | -S$885,226 | -S$0.07 (diluted) |
| Q4 FY2025 | S$168,500 | -S$2M | -S$0.14 (diluted) |
| Q3 FY2025 | S$205,081 | -S$868,349 | -S$0.07 (diluted) |
What are the financial strengths and risks for CytoMed Therapeutics (GDTC)?
Short answer · as of
What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -1.96 · Piotroski F 3. Trailing ratios: ROE -91.4% · ROA -75.1% · current ratio 2.64 · earnings yield -41.5% · free-cash-flow yield -49.9%.
Data-derived red flags
- Listing risk — at $0.755 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -1.96 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-91.4%) — the business is not currently generating profit on shareholder capital.
How does CytoMed Therapeutics compare with its peers?
Short answer
CytoMed Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $58.80 Nov 20, 2026 | $120B | 85 5-pillar Nov 18, 2026 | |
| $151.22 Nov 19, 2026 | $286B | 82 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| CytoMed Therapeutics (GDTC) — this page | $0.755 | $9.01M | 20 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GDTC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GDTC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about CytoMed Therapeutics (GDTC)?
Investor Questions: GDTC Stock
These answers are editorial: 1 of these 9 answers is drawn from the GDTC research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for GDTC?
GDTC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is GDTC a good stock to buy?
Stock Expert AI does not rate GDTC buy, sell or hold. CytoMed Therapeutics Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GDTC stock price today?
The last price recorded for CytoMed Therapeutics Limited (GDTC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for GDTC?
CytoMed Therapeutics Limited faces several risks, including regulatory challenges that could impact the approval of its therapies. Additionally, the company must navigate high operational costs associated with R&D, which could strain financial resources.
What are the key factors to evaluate for GDTC?
CytoMed Therapeutics Limited (GDTC) holds a MoonshotScore in the low range. No dividend yield, as the company is reinvesting in research and development to advance its product pipeline. Not financial advice.
How frequently does GDTC data refresh on this page?
GDTC's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GDTC's recent stock price performance?
CytoMed Therapeutics Limited (GDTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline focused on cell-based immunotherapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GDTC overvalued or undervalued right now?
CytoMed Therapeutics Limited (GDTC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of GDTC?
Fractional-share availability for CytoMed Therapeutics Limited (GDTC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com